Prostate Cancer Study Decision Tree
Prostate Cancer Timeline
Pre-Diagnosis
Kreftect Hair Study
Newly Diagnosed Treatment Planning
Active Surveillance
Primary Treatment
Biochemical Failure
mCSPC
- A phase 3, randomized, double-blind, placebo-controlled study of Mevrometostat (pf-06821497) with Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer
mCRPC
MEVPRO-1
- An open-label, multicenter study of subjects with Metastatic Castrate-Resistant Prostate cancer treated with Provenge and boosted with a single infusion of Sipuleucel-T to measure immune response
P24-2 Provenge Booster (COMING SOON)
- An open-label, multicenter study of participants with Metastatic Castrateresistant Prostate Cancer and high-risk genetic alterations previously treated with Provenge and with a single infusion retreatment with Sipuleucel-T
- A Randomized, Double-blind, Placebo-controlled, Phase III Study of Adjuvant Saruparib (AZD5305) in Patients with BRCAm Localized High-Risk Prostate Cancer Receiving Radiotherapy with Androgen Deprivation Therapy (EvoPAR-Prostate02)
- An Open-Label, Phase 1/1b Study of ORIC-944 as a Single Agent or in Combination with an Androgen Receptor Pathway Inhibitor in Patients with Metastatic Prostate Cancer
- A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2, + Best SupportiveCare Versus Best Supportive Care for Metastatic Castration-resistant Prostate Cancer